Development

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.

Batch-to-batch variability and impurities present critical challenges.

The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.

Webinar Dates/Times: Thursday, June 29, 2023 at 17:00 CEST | 11:00 EDT | 08:00 PDT

Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics.

BioChain has reached partnerships with NanoString and 10x Genomics to extend its spatial multiomics services.

The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.

Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics

Moderna and Merck reported that a combination therapy involving pembrolizumab and an mRNA demonstrated a 44% reduction in recurrence or death in cancer patients compared to non-combination treatments.

FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.

Webinar Date/Time: Wed, May 31, 2023 11:00 AM EDT

Stability and in vivo performance aren't just affected by lipids.

Lives are saved when time from vein to vein decreases.

Lonza and ABL Bio are collaborating on the development and manufacture of bispecific antibody product.

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.

Webinar Date/Time: Wed, May 3, 2023 11:00 AM EDT

The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.

FDA has spurred investment to create and develop 600 therapies.

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

Webinar Date/Time: Thursday, May 11th, 2023 at 10am EDT | 9am CDT | 3pm BST | 4pm CEST

Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.

Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.